Drug Profile

WVE 007

Alternative Names: INHBE GalNAc-siRNA -Wave Life Sciences; INHBE targeting siRNA - WaVe life Sciences; WVE-007

Latest Information Update: 31 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WaVe life Sciences
Class Drug conjugates; Hexosamines; Obesity therapies; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Obesity

Most Recent Events

30 Jul 2026 Wave Life Sciences plans phase IIa trial in Obeisty (Adjunctive therapy) in 2026
26 Mar 2026 Efficacy and adverse events data from phase I clinical trials in Obesity released by Wave Life Sciences
14 Dec 2025 Efficacy and adverse events data from phase II trial in Obesity released by Wave Life Sciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com